How to Reduce Suicidal Thoughts and Impulsivity in Depression

Suicidal Ideation Clinical Trial

— DEPIMPULSE  

Official title:

Controlled Randomized Non-comparative Trial Assessing Active Transcranial Direct Current Stimulation [tDCS] on Left Dorsoleteral Prefrontal Cortex Versus Active tDCS Active on Right Orbitofrontal Cortex to Treat Unipolar Depression

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05894980
• Other study ID #: 2022/724
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 2023
• Est. completion date: February 2026

Study information

• Verified date: May 2023
• Source: Centre Hospitalier Universitaire de Besancon
• Contact: Djamila BENNABI, MD PhD
• Phone: +33381219007
• Email: dbennabi[@]chu-besancon.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims at investigating if tDCS applied to left DLPFC or to right OFC to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode.

Description:

Depressive disorders are one of the most frequent pathologies in psychiatry. The lifetime prevalence of the characterized depressive episode is indeed particularly high, between 16.6% in the United States and 24.1% in France. Because of this high prevalence, and because they constitute a pathology with a high risk of suicidal behavior (SC), depressive disorders are a major target of medical strategies for suicide prevention. In addition to suicidal ideation, impulsivity, considered as the tendency to express spontaneous, excessive and/or unplanned behaviors, is recognized as being a major factor precipitating SCs. With a pilot, prospective, multicenter design, the perspectives of DEPIMPULSE include being able to develop an innovative therapeutic approach in the reduction of risky behaviors, in particular suicidal ideation, associated impulsivity, suicidal risk in patients suffering from depression, while improving our understanding of the behavioral aspects and associated cognitions. The treatment will be delivered during 5 consecutive days (D1 to D5). Baseline measures (D0) will be compared to those obtained after the treatment administration (last day of treatment (D5) and 2 weeks (+W2) and 1 month (+W4) after the end of treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: February 2026
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Man or woman older than 18 years oldRight-handed
• Signed Informed Consent form
• Subject affiliated to or beneficiary from a French social security regime
• Inpatient or outpatient at the Adult Psychiatry Service
• Diagnosis of Major Depressive Disorder according to the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and confirmation by the MINI Structured Clinical Interview
• MADRS score = 18
• Beck Scale for Suicide Ideation (BSS) score =8
• Under antidepressant treatment
• Absence of severe progressive neurologic and/or somatic pathologies (specially tumors, degenerative diseases)

Exclusion Criteria:

• tDCS contraindication
• Younger than 18 years old
• Left-handed
• under mood stabilizer and/or antiepileptic
• treated by ECT or rTMS or tDCS for the current eposide
• Subject under measure of protection or guardianship of justice
• Presence of other psychiatric pahtologies
• Subject beneficiary from a legal protection regime
• Subject unlikely to cooperate or low cooperation stated by investigator
• Subject not covered by social security
• Pregnant woman
• Subject being in the exclusion period of another study or provided for by the "National Volunteer File"

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Impulsive Behavior
• Suicidal Ideation
• Unipolar Depression

Intervention

Device:
• active tDCS stimulating left DLPFC
20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
• active tDCS stimulating right OFC
20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
• sham tDCS
20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC

Locations

Country	Name	City	State
France	CHU de Besançon	Besançon
France	CHU de Clermont-Ferrand	Clermont-Ferrand
France	Hôpital Chenevier, GH Henri Mondor	Créteil
France	CHU de Montpellier	Montpellier

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Besancon	Fondation FondaMental

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BSS scores	Difference of Beck's Scale for Suicide Ideation [BSS] score between Day 0 and Day 5, and between the arm active tDCS on left DLPFC and the arm active tDCS on right COF.; This scale contains 19 items to assess the risk level for suicide among general population. French version of this scale is designed for autovaluation.; Each item is quoted from 0 (no suicidal thoughts) to 2 (high degrees of suicidal intent).	Baseline (Day 0), Day 5 (D5)
Secondary	BSS scores	Difference of Beck's Scale for Suicide Ideation [BSS] score between Day 0 and Day 5, +W2 and +W4 between the 3 arms This scale contains 19 items to assess the risk level for suicide among general population. French version of this scale is designed for autovaluation.; Each item is quoted from 0 (no suicidal thoughts) to 2 (high degrees of suicidal intent).	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	C-SSRS scores	Compared scores from the Columbia-Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a clinician-rated tool that evaluates suicidal ideation and behavior. It is composed by 6 "yes/no" questions. High suicide risk is indicated when "yes" is answered to questions 4, 5 or 6.	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	BIS-10 scores	Compared scores from the French version of the Barratt Impulsiveness Scale (BIS-10). The French version of the BIS-10 is a self-rated 34 item questionnaire, composed by three subscales: motor-impulsivity, cognitive-impulsivity and non-planning-impulsivity. Each item is scored on a 0 to 4 points scale. Higher scores indicate higher levels of impulsivity.	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	UPPS scores	Compared scores from the Urgency, Premeditation (lack of), Perseverance (lack of), Sensation Seeking, Positive Urgency Impulsive Behavior Scale (UPPS-P). The French version of the UPPS-P is a self-rated 45 item scale, evaluating the following components: urgency, lack of premeditation, lack of perseverance and sensation seeking. Each item is scored on a base of 4 points. Higher scores indicate higher levels of impulsivity.	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	BART scores	Balloon Analogue Risk Task (BART), assessing risk-taking behavior	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	Cognitive assessment	Compared results from the experimental TEA, assessing cognitive functions.	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	Delay discounting with MCQ scores	Compared scores from the French version of the Monetary Choice Questionnaire (MCQ). The MCQ is a self-rated 27 item questionnaire which assessed the discounting. Delay discounting is the decline in the present value of a reward with delay to its receipt.; Example item: " Would you prefer 25€ today or 75€ in 15 days? " For each item, subjects must choose between a low immediate reward and a higher delayed reward.; Waiting times vary from 7 days to 186 days, and rewards are divided into 3 magnitudes: low (25-35€), medium (50-60€), high (75-85€).; This will allow assessing: the influence of the the magnitude of the difference between the two rewards proposed, the impact of the time on the reward's subjective value (speed at which the reward is devalued over time), reflected in the k index.; This index is calculated separately for each magnitude, and an average index is calculated for each subject.; The more the k index is high, the more the subject is considered impulsive.	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	Severity of depressive symptoms evaluated by the clinician	Score achieved on the validated clinician questionnaire Quick Inventory of Depressive Symptomatology (QIDS-C16) evaluating the severity of depressive symptoms.; The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	Severity of depressive symptoms evaluated by the patient	Score achieved on the validated self-reported (QIDS-SR16) evaluating the severity of depressive symptoms. QIDS-SR-16 is a standard questionnaire "The Quick Inventory of Depressive Symptomatology" (16-Item) (Self-Report). This covers questions on falling asleep, sleep during the night, waking up , sleeping too much, feeling sad ,appetite, weight, concentration , how they view themselves, thoughts of death and suicide, general interests, energy levels, feeling slowed down , feeling restless.	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	Quality of life measured with the EQ-5D-5L	Quality of life measured with the EQ-5D-5L	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS
Secondary	Psychological and Physical Pain-Visual Analogic Scale (PPP-VAS)	Likert scales from 0 (none) to 10 (maximum possible pain)	Baseline (Day 0), Day 5 (D5), Week 2(+W2) and Week 4 (+W4) post-tDCS